Although the risk of prostate cancer (PCa) varies across different ages and genetic risks, it’s unclear about the effects of genetic-specific and age-specific prostate-specific antigen (PSA) screening for PCa. This evidence concerns the gene KLK3 and posterior cortical atrophy.